AU2014340449B2 - Diagnosis and treatment of autoimmune diseases - Google Patents

Diagnosis and treatment of autoimmune diseases Download PDF

Info

Publication number
AU2014340449B2
AU2014340449B2 AU2014340449A AU2014340449A AU2014340449B2 AU 2014340449 B2 AU2014340449 B2 AU 2014340449B2 AU 2014340449 A AU2014340449 A AU 2014340449A AU 2014340449 A AU2014340449 A AU 2014340449A AU 2014340449 B2 AU2014340449 B2 AU 2014340449B2
Authority
AU
Australia
Prior art keywords
hmwk
protein
antibody
human
autoimmune disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014340449A
Other languages
English (en)
Other versions
AU2014340449A1 (en
Inventor
Burt Adelman
Andrew Nixon
Daniel J. Sexton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Takeda Pharmaceutical Co Ltd
Original Assignee
Takeda Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical Co Ltd filed Critical Takeda Pharmaceutical Co Ltd
Publication of AU2014340449A1 publication Critical patent/AU2014340449A1/en
Application granted granted Critical
Publication of AU2014340449B2 publication Critical patent/AU2014340449B2/en
Priority to AU2020200423A priority Critical patent/AU2020200423B2/en
Assigned to TAKEDA PHARMACEUTICAL COMPANY LIMITED reassignment TAKEDA PHARMACEUTICAL COMPANY LIMITED Request for Assignment Assignors: DYAX CORP.
Priority to AU2022204649A priority patent/AU2022204649B2/en
Priority to AU2024266697A priority patent/AU2024266697A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/86—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood coagulating time or factors, or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/564—Immunoassay; Biospecific binding assay; Materials therefor for pre-existing immune complex or autoimmune disease, i.e. systemic lupus erythematosus, rheumatoid arthritis, multiple sclerosis, rheumatoid factors or complement components C1-C9
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8139—Cysteine protease (E.C. 3.4.22) inhibitors, e.g. cystatin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/06—Gastro-intestinal diseases
    • G01N2800/065—Bowel diseases, e.g. Crohn, ulcerative colitis, IBS
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/10—Musculoskeletal or connective tissue disorders
    • G01N2800/101—Diffuse connective tissue disease, e.g. Sjögren, Wegener's granulomatosis
    • G01N2800/102—Arthritis; Rheumatoid arthritis, i.e. inflammation of peripheral joints
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • General Physics & Mathematics (AREA)
  • Rehabilitation Therapy (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AU2014340449A 2013-10-21 2014-10-17 Diagnosis and treatment of autoimmune diseases Active AU2014340449B2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU2020200423A AU2020200423B2 (en) 2013-10-21 2020-01-21 Diagnosis and treatment of autoimmune diseases
AU2022204649A AU2022204649B2 (en) 2013-10-21 2022-06-29 Diagnosis and treatment of autoimmune diseases
AU2024266697A AU2024266697A1 (en) 2013-10-21 2024-11-19 Diagnosis and treatment of autoimmune diseases

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361893542P 2013-10-21 2013-10-21
US61/893,542 2013-10-21
PCT/US2014/061242 WO2015061182A1 (en) 2013-10-21 2014-10-17 Diagnosis and treatment of autoimmune diseases

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020200423A Division AU2020200423B2 (en) 2013-10-21 2020-01-21 Diagnosis and treatment of autoimmune diseases

Publications (2)

Publication Number Publication Date
AU2014340449A1 AU2014340449A1 (en) 2016-06-02
AU2014340449B2 true AU2014340449B2 (en) 2019-10-31

Family

ID=52993412

Family Applications (4)

Application Number Title Priority Date Filing Date
AU2014340449A Active AU2014340449B2 (en) 2013-10-21 2014-10-17 Diagnosis and treatment of autoimmune diseases
AU2020200423A Active AU2020200423B2 (en) 2013-10-21 2020-01-21 Diagnosis and treatment of autoimmune diseases
AU2022204649A Active AU2022204649B2 (en) 2013-10-21 2022-06-29 Diagnosis and treatment of autoimmune diseases
AU2024266697A Pending AU2024266697A1 (en) 2013-10-21 2024-11-19 Diagnosis and treatment of autoimmune diseases

Family Applications After (3)

Application Number Title Priority Date Filing Date
AU2020200423A Active AU2020200423B2 (en) 2013-10-21 2020-01-21 Diagnosis and treatment of autoimmune diseases
AU2022204649A Active AU2022204649B2 (en) 2013-10-21 2022-06-29 Diagnosis and treatment of autoimmune diseases
AU2024266697A Pending AU2024266697A1 (en) 2013-10-21 2024-11-19 Diagnosis and treatment of autoimmune diseases

Country Status (14)

Country Link
US (3) US10101344B2 (cg-RX-API-DMAC7.html)
EP (2) EP3913364A1 (cg-RX-API-DMAC7.html)
JP (3) JP6657098B2 (cg-RX-API-DMAC7.html)
KR (3) KR102485948B1 (cg-RX-API-DMAC7.html)
CN (2) CN110658337B (cg-RX-API-DMAC7.html)
AU (4) AU2014340449B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016008975B1 (cg-RX-API-DMAC7.html)
CA (1) CA2927695C (cg-RX-API-DMAC7.html)
DK (1) DK3060908T3 (cg-RX-API-DMAC7.html)
ES (1) ES2873204T3 (cg-RX-API-DMAC7.html)
IL (4) IL284969B (cg-RX-API-DMAC7.html)
PL (1) PL3060908T3 (cg-RX-API-DMAC7.html)
PT (1) PT3060908T (cg-RX-API-DMAC7.html)
WO (1) WO2015061182A1 (cg-RX-API-DMAC7.html)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3456744B1 (en) * 2013-01-20 2023-03-29 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
US10101344B2 (en) * 2013-10-21 2018-10-16 Dyax Corp. Diagnosis and treatment of autoimmune diseases
AU2014340450B2 (en) 2013-10-21 2020-05-21 Takeda Pharmaceutical Company Limited Assays for determining plasma kallikrein system biomarkers
PL3365685T3 (pl) * 2015-10-19 2021-08-02 Dyax Corp. Test immunologiczny do wykrywania rozszczepionego wielkocząsteczkowego kininogenu
IL265195B2 (en) * 2016-09-16 2025-02-01 Dyax Corp Protein biomarkers for diseases related to the activation system
KR200490846Y1 (ko) 2019-04-09 2020-01-13 이대호 각도조절 브라켓
KR20230050770A (ko) 2021-10-08 2023-04-17 김경민 발로 열 수 있는 반려동물 울타리
JP2025522757A (ja) * 2022-06-30 2025-07-17 武田薬品工業株式会社 ラナデルマブ治療のためのタンパク質バイオマーカー

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025796A (en) * 1988-12-01 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject

Family Cites Families (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
CA1312564C (en) 1985-07-12 1993-01-12 Robert W. Colman Monoclonal antibodies to human plasma prekallikrein and methods of preparing and using same
US4908431A (en) 1986-01-22 1990-03-13 Temple University-Of The Commonwealth System Of Higher Education Monoclonal antibodies to human kininogen and methods of preparing same
US5047323A (en) 1986-01-22 1991-09-10 Temple University Of The Commonwealth System Of Higher Education Method for detecting human kininogen using monoclonal antibodies thereto
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
US4881175A (en) 1986-09-02 1989-11-14 Genex Corporation Computer based system and method for determining and displaying possible chemical structures for converting double- or multiple-chain polypeptides to single-chain polypeptides
KR960009766B1 (ko) 1986-09-10 1996-07-24 니혼 소오끼 세이야꾸 가부시기가이샤 생리 활성물질 측정법
US4882272A (en) 1986-10-01 1989-11-21 Temple University - Of The Commonwealth System Of Higher Education High molecular weight kininogen assay
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
CA2103059C (en) 1991-06-14 2005-03-22 Paul J. Carter Method for making humanized antibodies
US5472945A (en) 1991-08-13 1995-12-05 Temple University- Of The Commonwealth System Of Higher Education Modulation of blood pressure and inhibition of platelet activation with kininogen fragment
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6057287A (en) 1994-01-11 2000-05-02 Dyax Corp. Kallikrein-binding "Kunitz domain" proteins and analogues thereof
ES2227545T3 (es) 1994-01-11 2005-04-01 Dyax Corporation Proteinas y sus analogos del "dominio de kunitz" inhibidores de calicreina.
EP0852004B1 (en) 1995-10-11 2011-01-19 Luminex Corporation Multiplexed analysis of clinical specimens
JPH1084995A (ja) 1996-09-12 1998-04-07 Nippon Zoki Pharmaceut Co Ltd 血液凝固第ｘｉｉ因子活性化法
US5789261A (en) 1996-10-30 1998-08-04 Temple University Of The Commonwealth System Of Higher Education Solid phase immunoassay
US6242210B1 (en) 1997-05-20 2001-06-05 Actinova Limited Treatment of bacterial infections
EP0983303B1 (en) 1997-05-21 2006-03-08 Biovation Limited Method for the production of non-immunogenic proteins
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
JP4346798B2 (ja) 1999-08-19 2009-10-21 協和メデックス株式会社 Ｈｃｖコア抗原の検出または定量方法およびそれに用いる検出または定量試薬。
US6994852B1 (en) 1999-11-12 2006-02-07 Temple University-Of The Commonwealth System Of Higher Education Inhibition of angiogenesis by antibodies against high molecular weight kininogen domain 5
US7067713B2 (en) 2000-01-31 2006-06-27 Pharming Intellectual Property B.V. C1 Inhibitor produced in the milk of transgenic non-human mammals
US7678541B2 (en) 2000-11-21 2010-03-16 Hologic, Inc. Methods and compositions for the detection of a nucleic acid using a non-invasive cleavage reaction
JP2002221519A (ja) 2001-01-29 2002-08-09 Sysmex Corp 抗凝固剤およびそれを用いた抗凝固剤処理方法
US20040152633A1 (en) 2001-05-31 2004-08-05 Jorgensen Marianne Ulrich Kunitz-type sequences and polypeptides
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
US6913900B2 (en) 2001-08-29 2005-07-05 Nippon Zoki Pharmaceutical Co., Ltd. Plasma prekallikrein activation and kallikrein production assay
JP4106888B2 (ja) 2001-09-19 2008-06-25 カシオ計算機株式会社 液晶表示装置および携帯端末装置
US8148171B2 (en) 2001-10-09 2012-04-03 Luminex Corporation Multiplexed analysis of clinical specimens apparatus and methods
DE60333758D1 (de) 2002-06-07 2010-09-23 Dyax Corp Prevention und Verringerung von Ischemia
AU2003245676A1 (en) 2002-06-24 2004-01-06 Cornell Research Foundation, Inc. Exhaustive selection or rna aptamers against complex targets
US20070003552A1 (en) 2002-07-09 2007-01-04 Gebbink Martijn F B Cross-beta structure comprising amyloid binding proteins and methods for detection of the cross-beta structure, for modulating cross-beta structures fibril formation and for modulating cross-beta structure-mediated toxicity and method for interfering with blood coagulation
WO2004039487A1 (en) 2002-11-01 2004-05-13 Mcmaster University Multicomponent protein microarrays
WO2005024042A2 (en) 2003-09-04 2005-03-17 The Regents Of The University Of California Aptamers and methods for their in vitro selection and uses thereof
WO2005049826A1 (ja) 2003-11-22 2005-06-02 Ultizyme International Ltd. アプタマーを用いた標的分子の検出方法
EP1598428A1 (en) 2004-05-18 2005-11-23 Georg Dewald Methods and kits to detect Hereditary angioedema type III
JP2008515774A (ja) 2004-08-03 2008-05-15 ダイアックス コーポレイション ｈＫ１結合タンパク質
US7235530B2 (en) 2004-09-27 2007-06-26 Dyax Corporation Kallikrein inhibitors and anti-thrombolytic agents and uses thereof
WO2006040153A2 (en) 2004-10-13 2006-04-20 Ablynx N.V. Single domain camelide anti -amyloid beta antibodies and polypeptides comprising the same for the treatment and diagnosis of degenarative neural diseases such as alzheimer's disease
CN103254309B (zh) 2005-05-18 2017-09-26 埃博灵克斯股份有限公司 针对肿瘤坏死因子α的改进的纳米体TM
EP1981519B1 (en) * 2005-12-29 2017-12-27 Dyax Corp. Protease inhibition
CA2658523C (en) 2006-07-31 2012-06-12 Activesite Pharmaceuticals, Inc. Inhibitors of plasma kallikrein
EP2089712A4 (en) * 2006-11-22 2010-09-22 Life Technologies Corp BIOMARKERS OF AUTOIMMUNE DISEASES
WO2008100791A1 (en) 2007-02-16 2008-08-21 Rules-Based Medicine, Inc. Methods and kits for the diagnosis of sickle cell
WO2009026334A2 (en) * 2007-08-21 2009-02-26 Genzyme Corporation Treatment with kallikrein inhibitors
US20110154517A1 (en) 2007-10-22 2011-06-23 Georg Dewald Disorders of vasoregulation and methods of diagnosing them
KR20110057086A (ko) * 2008-07-07 2011-05-31 니폰 조키 세야쿠 가부시키가이샤 섬유근 통증의 검사법
US20110212104A1 (en) * 2008-11-03 2011-09-01 Schering Corporation Inflammatory bowel disease biomarkers and related methods of treatment
US20110318359A1 (en) 2008-12-02 2011-12-29 Feener Edward P Method for reducing blood pressure using inhibitors of plasma kallikrein
JP2013516389A (ja) 2009-01-06 2013-05-13 ダイアックス コーポレーション カリクレイン阻害剤による粘膜炎治療
FR2942233B1 (fr) 2009-02-19 2015-03-13 Lfb Biotechnologies Moyens pour la purification d'une proteine du plasma sanguin, et procedes pour sa mise en oeuvre
KR101077275B1 (ko) * 2009-05-07 2011-10-27 한국기초과학지원연구원 당단백질의 당쇄화를 이용한 암 진단 방법
JP5299179B2 (ja) * 2009-09-02 2013-09-25 株式会社リコー 画像形成装置
JO3244B1 (ar) 2009-10-26 2018-03-08 Amgen Inc بروتينات ربط مستضادات il – 23 البشرية
US9206123B2 (en) * 2009-12-18 2015-12-08 Activesite Pharmaceuticals, Inc. Prodrugs of inhibitors of plasma kallikrein
MX2012006913A (es) 2009-12-18 2012-08-23 Activesite Pharmaceuticals Inc Profarmacos de inhibidores de calicreina plasmatica.
SI3459564T1 (sl) 2010-01-06 2022-06-30 Takeda Pharmaceutical Company Limited Proteini, ki vežejo plazemski kalikrein
WO2012009447A2 (en) * 2010-07-13 2012-01-19 University Of Rochester THE cAMP/PKA/HDAC5 PATHWAY AND USES THEREOF
EP2645932B1 (en) 2010-12-02 2016-03-02 Becton, Dickinson and Company Blood collection devices containing blood stabilization agent
JP2014506257A (ja) 2011-01-06 2014-03-13 ダイアックス コーポレーション 血漿カリクレイン結合タンパク質
WO2012170945A2 (en) 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating kallikrein (klkb1) expression
WO2012170947A2 (en) * 2011-06-10 2012-12-13 Isis Pharmaceuticals, Inc. Methods for modulating factor 12 expression
EP3456744B1 (en) 2013-01-20 2023-03-29 Takeda Pharmaceutical Company Limited Evaluation and treatment of bradykinin-mediated disorders
KR20150141940A (ko) 2013-02-01 2015-12-21 벡톤 디킨슨 앤드 컴퍼니 접촉 경로를 저해하는 첨가제를 함유한 채혈 기구
AU2014340450B2 (en) 2013-10-21 2020-05-21 Takeda Pharmaceutical Company Limited Assays for determining plasma kallikrein system biomarkers
US10101344B2 (en) 2013-10-21 2018-10-16 Dyax Corp. Diagnosis and treatment of autoimmune diseases
EA038532B1 (ru) 2014-01-21 2021-09-10 Такеда Фармасьютикал Компани Лимитед Способ лечения наследственного ангионевротического отека (hae)
PL3365685T3 (pl) 2015-10-19 2021-08-02 Dyax Corp. Test immunologiczny do wykrywania rozszczepionego wielkocząsteczkowego kininogenu
AU2016372159B2 (en) 2015-12-15 2022-03-24 Takeda Pharmaceutical Company Limited Peptide quantitation assay for differentiating full-length high molecular weight kininogen (HMWK) and cleaved HMWK
WO2021154992A1 (en) * 2020-01-28 2021-08-05 Orgenesis Inc. Process and system for acellular therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5025796A (en) * 1988-12-01 1991-06-25 The United States Of America As Represented By The Department Of Health And Human Services Apparatus and methods for determining in vivo response to thermal stimulation in in an unrestrained subject

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ISORDIA-SALAS I ET AL, "The Role of Plasma High Molecular Weight Kininogen in Experimental Intestinal and Systemic Inflammation", ARCHIVES OF MEDICAL RESEARCH, vol. 36, no. 1, ISSN 0188-4409, (2005-01-01), pages 87 - 95, (2005-01-01) *
M. M. KHAN ET AL, "High-Molecular-Weight Kininogen Fragments Stimulate the Secretion of Cytokines and Chemokines Through uPAR, Mac-1, and gC1qR in Monocytes", ARTERIOSCLEROSIS, THROMBOSIS, AND VASCULAR BIOLOGY, 2006, vol. 26(10), pg 2260 *

Also Published As

Publication number Publication date
US10101344B2 (en) 2018-10-16
AU2022204649B2 (en) 2024-08-22
PT3060908T (pt) 2021-05-27
ES2873204T3 (es) 2021-11-03
IL284969B (en) 2022-07-01
US12061206B2 (en) 2024-08-13
JP2017500584A (ja) 2017-01-05
WO2015061182A1 (en) 2015-04-30
KR102665705B1 (ko) 2024-05-14
CA2927695C (en) 2022-03-01
DK3060908T3 (da) 2021-05-25
EP3060908B1 (en) 2021-02-24
IL293948A (en) 2022-08-01
IL275368A (en) 2020-07-30
CN110658337B (zh) 2023-06-16
KR20210107182A (ko) 2021-08-31
IL284969A (en) 2021-08-31
EP3060908A4 (en) 2017-03-22
JP2022191343A (ja) 2022-12-27
US10648990B2 (en) 2020-05-12
CN110658337A (zh) 2020-01-07
CA2927695A1 (en) 2015-04-30
CN105874332B (zh) 2019-11-12
IL245206B (en) 2020-06-30
BR112016008975A2 (pt) 2017-09-19
KR102295623B1 (ko) 2021-08-31
US20200371120A1 (en) 2020-11-26
AU2014340449A1 (en) 2016-06-02
JP2020091296A (ja) 2020-06-11
JP7541560B2 (ja) 2024-08-28
EP3913364A1 (en) 2021-11-24
JP6657098B2 (ja) 2020-03-04
AU2020200423A1 (en) 2020-02-13
PL3060908T3 (pl) 2021-10-25
KR102485948B1 (ko) 2023-01-06
US20190120862A1 (en) 2019-04-25
US20160252533A1 (en) 2016-09-01
AU2022204649A1 (en) 2022-07-21
KR20230010003A (ko) 2023-01-17
IL245206A0 (en) 2016-06-30
AU2024266697A1 (en) 2024-12-12
EP3060908A1 (en) 2016-08-31
KR20160089368A (ko) 2016-07-27
IL275368B (en) 2021-08-31
BR112016008975B1 (pt) 2023-02-28
JP7157089B2 (ja) 2022-10-19
AU2020200423B2 (en) 2022-03-31
CN105874332A (zh) 2016-08-17

Similar Documents

Publication Publication Date Title
AU2022204649B2 (en) Diagnosis and treatment of autoimmune diseases
US8637454B2 (en) Treatment of mucositis with kallikrein inhibitors
HK40058753A (en) Diagnosis and treatment of autoimmune diseases
AU2013205086A1 (en) Treatment of mucositis with kallikrein inhibitors

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
PC Assignment registered

Owner name: TAKEDA PHARMACEUTICAL COMPANY LIMITED

Free format text: FORMER OWNER(S): DYAX CORP.